Navigation Links
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology

Catalyst to Provide Proprietary Protein and Small Molecule Products for the Generation and Differentiation of Genomically-Unaltered Induced Pluripotent Stem (iPS) Cells

LA JOLLA, Calif. and BOSTON, April 23 /PRNewswire/ -- Fate Therapeutics, Inc. and Stemgent, Inc. announced today the formation of Catalyst, a collaborative one-of-a-kind program to provide pharmaceutical and biotechnology companies with the most advanced induced pluripotent stem (iPS) cell technology platform for drug discovery and development.

Catalyst will include the revolutionary protein-based reprogramming technology pioneered by Sheng Ding, Ph.D., published for the first time today in Cell Stem Cell. Dr. Ding, an associate professor of The Scripps Research Institute and scientific founder of Fate Therapeutics and Stemgent, is the first to report the creation of iPS cells using cell-penetrating proteins, a technique that effectively eliminates any risk of genetic modification. Catalyst will also include pioneering discoveries by Rudolf Jaenisch, M.D., a founding member of the Whitehead Institute, scientific founder of Fate Therapeutics and scientific advisory board member of Stemgent, who last month produced the first Parkinson's disease patient-derived iPS cells free of viral reprogramming factors.

In exchange for annual funding, Catalyst member companies will gain exclusive access to proprietary iPS cell technology, including specific iPS-derived cells for toxicity testing and primary screening. Fate Therapeutics and Stemgent will jointly guide and share the expenses of the development of products under Catalyst.

Revolutionary Products Available for First Time

"The creation of Catalyst represents the first time that many of these cutting edge technologies will be made available to industry," said Ian Ratcliffe, Stemgent's president and chief executive officer. "Dr. Ding's ground-breaking methods using proteins and small molecules to generate iPS cells and Dr. Jaenisch's innovative generation of a new way to model Parkinson's disease are just a few examples of the revolutionary products that will be made available - in commercial grade quality, reliability and scale - to Catalyst members."

Fate Therapeutics continues to be the leader in developing small molecules and biologics to modulate cell fate for regenerative medicine and therapeutic reprogramming indications, including hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. Stemgent accelerates the translation of stem cell science by providing application validated, proprietary reagents and tools developed by some of the world's leading stem cell scientists.

Commenting on Catalyst, Mr. Ratcliffe said, "Fate Therapeutics' stem cell biology expertise and Stemgent's superior reagent design and production capabilities make Catalyst an unmatched opportunity for the development of optimized small molecules and protein reagents for efficient and reproducible iPS cell generation and differentiation."

"Catalyst is the sole industry opportunity to access the most advanced iPS cell technology platform," said Paul Grayson, Fate Therapeutics' president and chief executive officer. "The Catalyst program represents a unique business collaboration amongst its participants to accelerate the translation of iPS cell technology into the discovery and development of safer and more effective therapeutics."

iPS cells are made by "reprogramming" fully differentiated mature cells, such as adult skin cells, to become pluripotent or stem-cell like and do not rely on the use of stem cells derived from embryos. Because iPS cells can differentiate into any cell type, iPS cells are considered of great importance to medicine because they can be used to model human diseases, discover and test drug candidates and develop personalized cell therapies. Previously, iPS cell generation required the delivery of genetic material through viruses or plasmids, which carry risks from insertion and are time-consuming, inefficient methods. Now, in collaboration with Dr. Ding, Fate Therapeutics and Stemgent have developed small molecules and proteins for the safe and efficient creation of high quality iPS cells that can reproducibly differentiate into essential cell types for drug discovery and development.

"Catalyst's technology - creating and differentiating iPS cells into distinct cell types - will uncover the essential epigenetic and gene expression profiles associated with the derivation of specific cell lineages," said Mr. Grayson. "These same technologies will prove critical in our discovery and development of conventional pharmaceuticals to guide cell fate for therapeutic benefit."

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating stem cell biology to develop therapeutics based on modulating cell fate and to enable a new drug discovery paradigm with the Company's proprietary induced-pluripotent stem (iPS) cell technology. The Company's first therapeutic candidate is scheduled to enter clinical trials in early 2009 in hematopoietic reconstitution. Fate Therapeutics is a private biotech company headquartered in La Jolla, CA. For more information, please visit

About Stemgent, Inc.

Stemgent advances stem cell science by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists. Stemgent's product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, viral-delivered transcription factors, matrices, cell lines, cytokines, antibodies, transfection reagents, and more. This unique product mix is designed to serve researchers who study stem cell biology and regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases. With dual headquarters in Boston, MA, and San Diego, CA, Stemgent is well positioned to serve these major research markets. For more information, please visit

Fate Therapeutics and Stemgent, along with Genzyme, Burrill & Company and WIRED Magazine, will be featured in a panel presentation entitled "Mastering Your (Cell) Fate: Stem Cells, iPSCs and the Future of Medicine" on May 18, 2009 at 2 p.m. at the 2009 BIO International Convention in Atlanta, GA.

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:11/24/2015)... Calif. , Nov. 24, 2015 Cepheid ... will be speaking at the following conference, and invited ... New York, NY      Tuesday, December 1, 2015 ... New York, NY      Tuesday, December 1, 2015 ... Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):